Table 2.
Pharmacokinetics of pyronaridine in plasma in healthy and malaria-infected adults
| Reference | n | Regimen | PYR dose (mg) |
C
max
(ng/mL) |
T
max
(h) |
AUC0−∞(ng/mL day) |
t
1/2
(days) |
|---|---|---|---|---|---|---|---|
| Healthy adults | |||||||
| Jayaraman et al.40 | 1 | PYR single dose | 400a | 495.8 | 0.5 | 2154 | 10.4 |
| Babalola et al.42 | 1 | PYR single dose | 400b | 76.2 | 1 | 27.62c | — |
| Malaria adults | |||||||
| Ramanathan et al.41 | 5 | PYR 3 day course | 720a | 120 ± 30 | 80 | 1225 ± 545 | 8.1 ± 2 |
All values are expressed as mean ± SD unless indicated otherwise. PYR, pyronaridine tetraphosphate.
PYR in capsule formulation.
PYR in tablet formulation.
The value represents AUC0–12h.